Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide versus oral antidiabetic drugs added to metformin in primary care type 2 diabetes
2015-002417-29Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2015
- Modality
- Small Molecules, Peptides, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of liraglutide, sitagliptin, linagliptin, saxagliptin, vildagliptin and 6 more in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Time to inadequate glycaemic control. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-002417-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002417-29.